Epigenetics in Inflammatory Breast Cancer: Biological Features and Therapeutic Perspectives

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade Estadual Paulista (Unesp)-
Autor(es): dc.contributorHermínio Ometto Foundation-
Autor(es): dc.contributorUniversity of Southern Denmark-
Autor(es): dc.creatorFaldoni, Flavia Lima Costa [UNESP]-
Autor(es): dc.creatorRainho, Cláudia Aparecida [UNESP]-
Autor(es): dc.creatorRogatto, Silvia Regina-
Data de aceite: dc.date.accessioned2022-02-22T00:30:30Z-
Data de disponibilização: dc.date.available2022-02-22T00:30:30Z-
Data de envio: dc.date.issued2020-12-11-
Data de envio: dc.date.issued2020-12-11-
Data de envio: dc.date.issued2020-05-08-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.3390/cells9051164-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/200400-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/200400-
Descrição: dc.descriptionEvidence has emerged implicating epigenetic alterations in inflammatory breast cancer (IBC) origin and progression. IBC is a rare and rapidly progressing disease, considered the most aggressive type of breast cancer (BC). At clinical presentation, IBC is characterized by diffuse erythema, skin ridging, dermal lymphatic invasion, and peau d'orange aspect. The widespread distribution of the tumor as emboli throughout the breast and intra- and intertumor heterogeneity is associated with its poor prognosis. In this review, we highlighted studies documenting the essential roles of epigenetic mechanisms in remodeling chromatin and modulating gene expression during mammary gland differentiation and the development of IBC. Compiling evidence has emerged implicating epigenetic changes as a common denominator linking the main risk factors (socioeconomic status, environmental exposure to endocrine disruptors, racial disparities, and obesity) with IBC development. DNA methylation changes and their impact on the diagnosis, prognosis, and treatment of IBC are also described. Recent studies are focusing on the use of histone deacetylase inhibitors as promising epigenetic drugs for treating IBC. All efforts must be undertaken to unravel the epigenetic marks that drive this disease and how this knowledge could impact strategies to reduce the risk of IBC development and progression.-
Descrição: dc.descriptionDepartment of Gynecology and Obstetrics Medical School São Paulo State University (UNESP)-
Descrição: dc.descriptionHermínio Ometto Foundation-
Descrição: dc.descriptionDepartment of Chemical and Biological Sciences Institute of Biosciences São Paulo State University (UNESP)-
Descrição: dc.descriptionDepartment of Clinical Genetics Lillebaelt University Hospital of Southern Denmark Institute of Regional Health Research University of Southern Denmark-
Descrição: dc.descriptionDepartment of Gynecology and Obstetrics Medical School São Paulo State University (UNESP)-
Descrição: dc.descriptionDepartment of Chemical and Biological Sciences Institute of Biosciences São Paulo State University (UNESP)-
Idioma: dc.languageen-
Relação: dc.relationCells-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectDNA methylation-
Palavras-chave: dc.subjectepigenetic therapy-
Palavras-chave: dc.subjecthistone deacetylases-
Palavras-chave: dc.subjecthistone modifications-
Palavras-chave: dc.subjectinflammatory breast cancer-
Título: dc.titleEpigenetics in Inflammatory Breast Cancer: Biological Features and Therapeutic Perspectives-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.